Role of Ca125 Monitoring in Post Treatment Epithelial Ovarian Cancer Patients

Authors

  • D. K. Vijay kumar Professor and Head Amrita Institute of Medical Sciences and Research Centre Surgical and Gynaecologic Oncology Amrita Lane, AIMS, Ponekkara Kochi, Kerala.

DOI:

https://doi.org/10.37591/rrjooh.v4i2.1370

Abstract

The role of routine CA125 monitoring after therapy in epithelial ovarian CA has been questioned after the results of the MRC OV-05/EORTC 55985 study have been published. However, the role of hormonal agents like Tamoxifen or Letrezole in the setting of asymptomatic rise in CA125 has not been addressed in this study, as the treatment group received second-line chemotherapy. The GOG has looked into the role of Tamoxifen and also compared it with other agents like Thalidomide. Tamoxifen seems to be better than Thalidomide in this setting. While the EORTC study compared chemotherapy versus no-treatment, the GOG study compared Tamoxifen versus Thalidomide. Thus the question of no-treatment versus Tamoxifen or chemotherapy versus Tamoxifen in this group of patients has not been addressed. Other agents tried include anti-angiogenic urokinase plasminogen inhibitor A6 and also the aromatase inhibitor Letrezole. Both have shown minimal activity and may be used to increase the progression-free interval in asymptomatic patients with a rising CA125. Normal CA125 levels may help reassure patients on follow-up especially those with non-specific symptoms, though all recurrences need not have an elevated CA125. Thus, CA125 monitoring may be useful as a marker to guide further investigations, for patient reassurance and for decision on initiating oral hormonal agents like Tamoxifen and Letrezole.

 

Keywords: Ca125, post treatment, harmonal agents, epithelial ovarian cancer, chemotherapy

Cite this Article

Vijaykumar DK. Role of Ca125 monitoring in post treatment epithelial ovarian cancer patients.Research and Reviews: Journal of Oncology and Hematology (RRJoOH). 2015; 4(2):   17–20p.

Downloads

Published

2019-04-12

Issue

Vol. 4 No. 2 (2015)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.